Labcorp announced the launch of Labcorp Plasma Detect?, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) molecular residual disease (MRD) solution in early stage colon cancer to identify patients at increased risk of recurrence after surgery or adjuvant chemotherapy (ACT). This solution, which is designed for research use but also suitable for clinical applications, can be applied across solid tumors with a scalable and standardized approach to facilitate faster turnaround times while maintaining high analytical performance. The launch of the Labcorp Plasma Detect MRD solution further enhances Labcorp's leadership in precision oncology across the solid tumor oncology care continuum.

Labcorp Plasma Detect builds on the successful deployment of two existing liquid biopsy platforms ? Labcorp® Plasma Focus?, a targeted approach, and Labcorp® Plasma Complete?, a comprehensive profiling solution, both with utility for clinical research and clinical applications. All three solutions were developed by Personal Genome Diagnostics Inc. (PGDx®), a Labcorp company, and are performed in the PGDx Baltimore CAP-accredited and CLIA-certified laboratory.

The Labcorp Plasma Detect integrated whole-genome sequencing sample-to-report workflow was developed under PGDx's quality management system and design control process, undergoing rigorous analytical and clinical validation to demonstrate high sensitivity and specificity for ctDNA detection. It is backed by Labcorp's global network and expertise and does not require the manufacturing of patient-specific, bespoke panels, making it feasible to implement for research programs and clinical trials globally. Labcorp Plasma Detect is currently clinically validated for early-stage colon cancer, with ongoing efforts to expand into other indications, including lung cancer and bladder cancer.

In collaboration with the Netherlands Cancer Institute (NKI), Labcorp Plasma Detect validation data will be presented during a podium presentation ? Clinical validity of post-surgery circulating tumor DNA testing in stage III colon cancer patients treated with adjuvant chemotherapy: the PROVENC3 study ? at the annual meeting of the American Association for Cancer Research® (AACR®).

Labcorp Plasma Detect will also be used to support the MEDOCC-CrEATE trial, an interventional, randomized study that will provide insight into the willingness of stage II colon cancer patients to be treated with ACT and whether ACT can prevent recurrences in a high-risk population.